This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to The Johns Hopkins University focuses on evaluating the effects of prostate-specific membrane antigen (PSMA)-based radiopharmaceutical therapy (PSMA-RPT) on glutamine metabolism in prostate cancer (PC) and renal cell carcinoma (RCC). The total funding amount is $545,078, awarded from February 1, 2025 through January 31, 2030.
The research aims to: 1) assess how PSMA-RPT affects glutaminolysis in PC and RCC cell lines as monotherapy and in combination with pharmacological or genetic inhibition of glutamine metabolism pathways, to determine the role in DNA damage; and 2) evaluate the effects of PSMA-RPT as monotherapy and in combination with glutaminolysis inhibitors in preclinical PC and RCC models. This work seeks to uncover insights into PSMA-RPT-induced metabolic changes associated with DNA damage and develop mechanism-driven combination therapies to enhance the efficacy of radiopharmaceutical cancer treatments.
Generated 3/4/25, 4:27 AM